Fibrogen Inc FGEN
We take great care to ensure that the data presented and summarized in this overview for FIBROGEN INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding FGEN
View all-
Armistice Capital, LLC New York, NY8.5MShares$44.8 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.86MShares$30.9 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA3.91MShares$20.6 Million0.0% of portfolio
-
Primecap Management CO Pasadena, CA3.74MShares$19.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.41MShares$12.7 Million0.0% of portfolio
-
Marshall Wace, LLP London, X02.21MShares$11.7 Million0.0% of portfolio
-
Pictet Asset Management Sa Geneva 73, V81.37MShares$7.25 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.08MShares$5.69 Million0.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny676KShares$3.56 Million0.0% of portfolio
-
Two Sigma Investments, LP New York, NY584KShares$3.08 Million0.0% of portfolio
Latest Institutional Activity in FGEN
Top Purchases
Top Sells
About FGEN
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Insider Transactions at FGEN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2025
|
James A Schoeneck |
BUY
Open market or private purchase
|
Indirect |
23,567
+37.27%
|
$117,835
$5.07 P/Share
|
|
Mar 24
2025
|
Thane Wettig CEO |
BUY
Open market or private purchase
|
Direct |
145,000
+21.07%
|
$0
$0.35 P/Share
|
|
Mar 21
2025
|
James A Schoeneck |
BUY
Open market or private purchase
|
Indirect |
50,000
+11.8%
|
$0
$0.34 P/Share
|
|
Mar 20
2025
|
James A Schoeneck |
BUY
Open market or private purchase
|
Indirect |
250,000
+43.58%
|
$0
$0.35 P/Share
|
|
Mar 06
2025
|
David De Lucia Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,325
-1.96%
|
$0
$0.39 P/Share
|
|
Mar 06
2025
|
Christine Chung SVP, CHINA OPERATIONS |
SELL
Payment of exercise price or tax liability
|
Direct |
7,430
-1.23%
|
$0
$0.39 P/Share
|
|
Mar 06
2025
|
Christine Chung SVP, CHINA OPERATIONS |
BUY
Grant, award, or other acquisition
|
Direct |
781
+0.26%
|
-
|
|
Mar 06
2025
|
Thane Wettig CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
22,405
-2.67%
|
$0
$0.39 P/Share
|
|
Mar 06
2025
|
Thane Wettig CEO |
BUY
Grant, award, or other acquisition
|
Direct |
781
+0.2%
|
-
|
|
Dec 07
2024
|
Juan Graham CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,066
-0.64%
|
$0
$0.34 P/Share
|
|
Dec 06
2024
|
Christine Chung SVP, CHINA OPERATIONS |
SELL
Payment of exercise price or tax liability
|
Direct |
2,792
-0.92%
|
$0
$0.34 P/Share
|
|
Dec 06
2024
|
Thane Wettig CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,363
-0.56%
|
$0
$0.34 P/Share
|
|
Dec 06
2024
|
Juan Graham CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,446
-0.86%
|
$0
$0.34 P/Share
|
|
Sep 07
2024
|
Juan Graham CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,065
-0.63%
|
$0
$0.39 P/Share
|
|
Sep 06
2024
|
Christine Chung SVP, CHINA OPERATIONS |
SELL
Payment of exercise price or tax liability
|
Direct |
17,395
-5.41%
|
$0
$0.39 P/Share
|
|
Sep 06
2024
|
Thane Wettig CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,363
-0.56%
|
$0
$0.39 P/Share
|
|
Sep 06
2024
|
Juan Graham CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
16,050
-8.7%
|
$0
$0.39 P/Share
|
|
Aug 01
2024
|
Thane Wettig CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
20,840
-4.68%
|
$0
$0.47 P/Share
|
|
Jun 22
2024
|
Thane Wettig CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
782
-0.18%
|
$782
$1.13 P/Share
|
|
Jun 12
2024
|
Deyaa Adib Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
22,123
+21.22%
|
$22,123
$1.17 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.56K shares |
|---|---|
| Open market or private purchase | 469K shares |
| Payment of exercise price or tax liability | 97.5K shares |
|---|